SEARCH:   Advanced

Blood, Vol. 111, Issue 2, 874-877, January 15, 2008 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 –938A>C promoter single nucleotide polymorphism Blood Majid et al. 111: 874 Supplemental materials for: Majid et al Files in this Data Supplement: Document 1. Supplemental methods (PDF, 102 KB) Table S1. Clinical characteristics of low BCL2-protein expressing CLL (PDF, 17.7 KB) - WCC denotes WCC at diagnosis; Rx number of different chemotherapy/antibody regimens. Note that despite expressing lower amounts of BCL2 protein, four cases were nonetheless resistant to fludarabine, and five showed high-level of BCL2 RNA, comparable to that observed in the lymphoma cell line SC-1 without comparable level of protein expression (shaded boxes). n/a – not applicable Figure S1. Levels of BCL2 protein are relatively constant in CLL at different time points before and after therapy (JPG, 76.3 KB) - Sequential patient samples were taken before (a) and after (b) treatment. The levels of BCL2 remain relatively constant. Figure S2. CLL with t(14;18)(q32;q21) showing expression of BCL2 comparable to that of the SC-1 cell line (JPG, 25.8 KB) - Apart from exhibiting t(14;18)(q32;q21) by interphase FISH, these five cases were otherwise typical CLL. H denotes HRC-57 cell line. Figure S3. 13q homozygous deletion samples showing expression of BCL2 comparable to that of the SC-1 cell line (JPG, 35.1 KB) - This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020